Table 6.

Sensitivity Analyses of 2030 Prevalence for Adults 30 Years or Older

Analysis	CKD	Stage 3a+	Stage 3b+	Stage 4+	Stage 5
Baseline	16.52	10.72	2.74	0.73	0.22
eGFR slope +50%	24.26	19.64	6.52	1.76	0.51
eGFR slope −50%	11.32	4.42	1.03	0.23	0.06
Stages 3 and 4 mortality +10%	16.31	2.61	0.69	0.69	0.20
Stages 3 and 4 mortality −10%	16.75	10.96	2.89	0.78	0.23
Stage 5 mortality +25%	16.49	10.68	2.70	0.69	0.18
Stage 5 mortality −25%	16.58	10.78	2.80	0.79	0.28
Age-specific CKD mortality rates	16.39	10.58	2.65	0.70	0.21
Diabetes incidence +33%	16.68	10.72	2.82	0.77	0.22
Diabetes incidence −33%	16.38	10.72	2.61	0.68	0.20
Proteinuria incidence +15%	17.00	10.72	2.74	0.73	0.22
Proteinuria incidence −15%	16.01	10.70	2.72	0.72	0.22
Hypertension incidence +10%	16.57	10.71	2.75	0.73	0.22
Hypertension incidence −10%	16.49	10.74	2.75	0.73	0.22

Note: Values are given as percentage. CKD stage 3a+ shows the projected percentage of persons with eGFR < 60 mL/min/1.73 m² in 2030. CKD stages 3b+, 4+, and 5 are defined in a similar manner, with eGFR cutoff points of 45, 30, and 15 mL/min/1.73 m², respectively.

Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.